145 related articles for article (PubMed ID: 6122893)
21. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
23. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
24. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
[No Abstract] [Full Text] [Related]
25. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Mahler C; Denis L
Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
[TBL] [Abstract][Full Text] [Related]
27. Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.
Maezawa H; Komatsu H; Kawaoi A; Ueno A
Int J Urol; 1997 Jul; 4(4):411-6. PubMed ID: 9256333
[TBL] [Abstract][Full Text] [Related]
28. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
[TBL] [Abstract][Full Text] [Related]
30. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
[TBL] [Abstract][Full Text] [Related]
31. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
32. Effects of chronic treatment with an LHRH agonist on the secretion of LH, FSH and testosterone in the ram.
Fraser HM; Lincoln GA
Biol Reprod; 1980 Mar; 22(2):269-76. PubMed ID: 6769512
[No Abstract] [Full Text] [Related]
33. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
[TBL] [Abstract][Full Text] [Related]
34. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
35. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
36. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
[TBL] [Abstract][Full Text] [Related]
37. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
38. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
[TBL] [Abstract][Full Text] [Related]
39. Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation.
Lindner C; Braendle W; Lichtenberg V; Bettendorf G
Gynecol Obstet Invest; 1990; 29(2):132-9. PubMed ID: 2139863
[TBL] [Abstract][Full Text] [Related]
40. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
Kerle D; Williams G; Ware H; Bloom SR
Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
